Top

Published in:

01-08-2021 | Radiotherapy | Case Report

A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy

Authors: Miha Orazem, Cédric Draulans, Mathieu Spaas, Eric Van Cutsem, Marina Debecker, Gert De Meerleer, Sabine Tejpar, Jeroen Dekervel, Karin Haustermans

Published in: Clinical Journal of Gastroenterology | Issue 4/2021

Abstract

Purpose

Multimodality treatments combining radiotherapy, immune therapy and/or targeted therapy are under heavy investigation. Promising data from clinical trials are emerging, nevertheless unexpected interactions and adverse events should not be overlooked.

Case presentation

Here we present a case study of a patient with metastatic colon adenocarcinoma treated sequentially with a chemotherapy/targeted therapy combination, immune checkpoint inhibitors and ultra-hypofractionated radiotherapy. After radiation treatment, the patient developed extensive posterior abdominal wall wounds coinciding with regression of the irradiated metastatic tumour mass and marked elevation of the inflammation parameters.

Conclusion

This case represents an unusual fatal wound complication after palliative ultra-hypofractionated radiotherapy. Further research into synergistic effects of sequential radiotherapy and anti-angiogenesis therapy may provide an advantage in anticipating severe sequelae.

Nguyen QN, Chun SG, Chow E, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5:872–8. https://doi.org/10.1001/jamaoncol.2019.0192.CrossRefPubMedPubMedCentral

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5.CrossRefPubMed

Gong J, Le TQ, Massarelli E, et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018. https://doi.org/10.1186/s40425-018-0361-7.CrossRefPubMedPubMedCentral

Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–8. https://doi.org/10.1200/JCO.2005.10.017.CrossRefPubMed

Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44. https://doi.org/10.1200/JCO.2006.09.6305.CrossRefPubMed

Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48. https://doi.org/10.1016/j.ejca.2015.11.016.CrossRefPubMed

Kroeze SGC, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev. 2017;53:25–37. https://doi.org/10.1016/j.ctrv.2016.11.013.CrossRefPubMed

Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-509. https://doi.org/10.1016/S1470-2045(15)00007-8.CrossRefPubMed

Kroeze SGC, Fritz C, Basler L, et al. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries. Strahlentherapie Und Onkol. 2019;195:199–206. https://doi.org/10.1007/s00066-018-01422-5.CrossRef

10.

Boustani J, Grapin M, Laurent PA, et al. The 6th R of radiobiology: reactivation of anti-tumor immune response. Cancers (Basel). 2019;11(6):860. https://doi.org/10.3390/cancers11060860 (Published 2019 Jun 20).CrossRef

11.

Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: from “systemic” to “multisite.” Clin Cancer Res. 2020;26(12):2777–82. https://doi.org/10.1158/1078-0432.CCR-19-2034.CrossRefPubMed

12.

Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2020. https://doi.org/10.1016/S2213-2600(20)30391-X.CrossRefPubMed

13.

Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7(1):165. https://doi.org/10.1186/s40425-019-0645-6.CrossRefPubMedPubMedCentral

14.

Shinagare AB, Howard SA, Krajewski KM, et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. Am J Roentgenol. 2012;199:1259–65. https://doi.org/10.2214/AJR.12.8782.CrossRef

15.

Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10:559–68. https://doi.org/10.1016/S1470-2045(09)70112-3.CrossRefPubMed

16.

Keung EZ, Liu X, Nuzhad A, et al. Immunocompromised status in patients with necrotizing soft-tissue infection. JAMA Surg. 2013;148:419–26. https://doi.org/10.1001/jamasurg.2013.173.CrossRefPubMed

17.

Pollom EL, Deng L, Pai RK, et al. Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:568–76. https://doi.org/10.1016/j.ijrobp.2015.02.016.CrossRefPubMedPubMedCentral

18.

de Campos-Lobato LF, Vogel JD. Enterocutaneous fistula associated with malignancy and prior radiation therapy. Clin Colon Rectal Surg. 2010;23(3):176–81. https://doi.org/10.1055/s-0030-1262985.CrossRef

19.

Borst G, Sonke J, Belderbos J, et al. Normal tissue complication probability after hypofractionation increased due to the high dose per fraction or the high total biological equivalent dose? Radiother Oncol. 2010;94(3):388. https://doi.org/10.1016/j.radonc.2010.01.023.CrossRefPubMed

Title: A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy
Authors: Miha Orazem
Cédric Draulans
Mathieu Spaas
Eric Van Cutsem
Marina Debecker
Gert De Meerleer
Sabine Tejpar
Jeroen Dekervel
Karin Haustermans
Publication date: 01-08-2021
Publisher: Springer Singapore
Keywords: Radiotherapy
Targeted Therapy
Bevacizumab
Checkpoint Inhibitors
Cytostatic Therapy
Published in: Clinical Journal of Gastroenterology / Issue 4/2021
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-021-01399-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2021

Successful hemostasis of bleeding gastric inflammatory fibroid polyp by endoscopic treatment in a patient with severe COVID-19

Immunoglobulin A vasculitis without purpura in an elderly female patient: a case report

Emergency lower gastrointestinal endoscopy performed safely in a COVID-19 patient on extracorporeal membrane oxygenation (ECMO) with hemorrhagic shock

A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma

A resected case of ruptured peritoneal metastasis of hepatocellular carcinoma

Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials